Table 1.
Clinical and pathological features of stage I EOC patients of reproductive age
| Variables | All (N = 108) | RS (N = 56; 51.9%) | FSS (N = 52; 48.1%) | P value |
|---|---|---|---|---|
| Age at diagnosis(years) Median(min–max) |
30(16–40) | 35(17–40) | 25(16–40) | < 0.001 |
| ≤ 30 | 55(50.9%) | 10(17.9%) | 45(86.5%) | < 0.001 |
| > 30 | 53(49.1%) | 46(82.1%) | 7(13.5%) | |
| Nulliparous—N(%) | 67(62.0%) | 18(32.1%) | 49(94.2%) | < 0.001 |
| Primary tumor size(cm) Median(min–max) |
12.0(3.0–40.0) | 10.0(3.0–28.0) | 15.0(4.0–40.0) | 0.002 |
| Side of ovarian tumor—N(%) | 0.087 | |||
| Both | 5(4.6%) | 5(8.9%) | 0(0%) | |
| Left | 56(51.9%) | 28(50.0%) | 28(53.8%) | |
| Right | 47(43.5%) | 23(41.1%) | 24(46.2%) | |
| Pretreatment tumor markers—N(%) | 0.084 | |||
| Normal | 55(50.9%) | 33(58.9%) | 22(42.3%) | |
| Elevated | 53(49.1%) | 23(41.1%) | 30(57.7%) | |
| Histology—N(%) | < 0.001 | |||
| Mucinous | 52(48.2%) | 14(25.0%) | 38(73.1%) | |
| Serous | 9(8.3%) | 8(14.3%) | 1(1.9%) | |
| Endometrioid | 27(25.0%) | 16(28.6%) | 11(21.2%) | |
| CCC | 20(18.5%) | 18(32.1%) | 2(3.8%) | |
| Grade—N(%) | < 0.001 | |||
| G1 | 72(66.7%) | 27(48.2%) | 45(86.5%) | |
| G2 | 12(11.1%) | 8(14.3%) | 4(7.7%) | |
| G3 | 4(3.7%) | 3(5.4%) | 1(1.9%) | |
| CCC | 20(18.5%) | 18(32.1%) | 2(3.9%) | |
| FIGO stage—N(%) | 0.633 | |||
| IA–B | 36(33.3%) | 17(30.4%) | 19(36.5%) | |
| IC1 | 55(50.9%) | 31(55.3%) | 24(46.2%) | |
| IC2–3 | 17(15.7%) | 8(14.3%) | 9(17.3%) | |
| Approach of staging—N(%) | 0.932 | |||
| LPS | 5(4.6%) | 3(5.4%) | 2(3.8%) | |
| LPT | 103(95.4%) | 53(94.6%) | 50(96.2%) | |
| Surgical staging procedures—N(%) | ||||
| Omentectomy | 104(96.3%) | 56(100%) | 48(92.3%) | 0.109 |
| Appendectomy | 104(96.3%) | 56(100%) | 48(92.3%) | 0.109 |
| Lymphadenectomy | 103(95.4%) | 55(98.2%) | 48(92.3%) | 0.317 |
| Para-aortic LN excision | 58 (53.7%) | 34(60.7%) | 24(46.2%) | 0.186 |
| Number of LN-median(min–max) | 18(2–57) | 17(5–53) | 22(2–57) | 0.215 |
| Chemotherapy—N(%) | 0.006 | |||
| Taxane platinum | 52(48.1%) | 31(55.4%) | 21(40.4%) | |
| Platinum-based regimen | 31(28.7%) | 19(33.9%) | 12(23.1%) | |
| No chemotherapy | 25(23.2%) | 6(10.7%) | 19(36.5%) | |
| Cycles-median(min–max) | 4(3–9) | 6(3–9) | 3(3–9) | 0.001 |
| EAOC—N(%) | 21(19.4%) | 17(30.4%) | 4(7.7%) | 0.006 |
| EC—N(%) | 4(3.7%) | 4(7.1%) | 0(0%) | 0.146 |
| Follow–up (months) Median(min–max) |
83(9–216) | 96(9–216) | 60(34–209) | 0.026 |
RS radical surgery, FSS fertility-sparing surgery, LPS laparoscopy, LPT laparotomy, EOC epithelial ovarian cancer, CCC clear-cell carcinoma, EAOC endometriosis-associated ovarian cancer, EC endometrial carcinoma